Mogamulizumab

莫格利珠单抗

Report date: 2026/02/17 20:00:13
First In Class

Base Information

Drug NameMogamulizumab
Drug Alias Name莫加利珠单抗mogamulizumab-kpkcPoteligeo惠尔金KW-0761 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionC-C chemokine receptor type 4 antagonists
TargetsC-C chemokine receptor type 4
Therapy Area/IndicationsSolid tumoursAsthmaLymphoma, T-Cell, Peripheral +[11] 
Global Approved IndicationsSezary SyndromeMycosis FungoidesLymphoma, T-Cell
Approved Indications in ChinaSezary SyndromeMycosis Fungoides
Original Approved Country/TerritoryJapan
Original Approved Date2012/03/30
Country/TerritoryBelgiumUnited StatesNetherlands +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKyowa KirinKyowa Hakko Kirin Co LtdNational Cancer Institute +[6] 
Inactive CompaniesKyowa Hakko Kirin Pharma IncKyowa Kirin IncKyowa Kirin Co Ltd +[8] 
Active IndicationsLymphoma, T-Cell, PeripheralSezary SyndromeMycosis Fungoides +[6] 
Inactive IndicationsSolid tumoursAsthmaLymphoma, Extranodal NK-T-Cell +[5] 

Other Information

ATC CodeL01XC25
Related LinksWikipediaKEGG